Abstract:A series of novel nifuroxazide derivatives based on 4 or 5‐nitropyrrole skeleton were synthesized. Their antitumor activity was tuned by varying benzyl substituents on pyrrole and/or hydroxyl substituent on benzene. The 30, forms hydrogen bonds of STAT3 with low binding energy, and has the best antitumor activity against nasopharyngeal carcinoma in vitro, IC50=0.80 μM. Herein, we reported 36 novel nifuroxazide derivatives based on 4 or 5‐nitropyrrole skeleton for the first time. The influence of the benzyl substituents on the pyrrole ring and/or hydroxyl substituent on the benzene ring for the anticancer activity was investigated. Most of the designed derivatives were active at micromolar or submicromolar concentrations. The most promising compounds, namely derivatives (E)‐2,3‐dihydroxy‐N′‐((5‐nitro‐1‐(4‐(trifluoromethyl)benzyl)‐1H‐pyrrol‐2‐yl)methylene) benzohydrazide (18), (E)‐N′‐((1‐(4‐fluorobenzyl)‐5‐nitro‐1H‐pyrrol‐2‐yl) methylene)‐2,3‐dihydroxybenzohydrazide (24), and (E)‐N′‐((1‐(3‐fluorobenzyl)‐5‐nitro‐1H‐pyrrol‐2‐yl) methylene)‐2,3‐dihydroxybenzohydrazide (30), exhibited better antitumor activity than nifuroxazide in vitro, with IC50 values ranging from 0.80 to 5.18 μM on CNE2 (human nasopharyngeal carcinoma cell line) and SUNE1 (human nasopharyngeal carcinoma cell line). Docking results indicated that compounds 24 and 30 interacted with the SRC homology 2 (SH2) and carboxyl‐terminal transactivation domain of STAT3 (the signal transducer and activator of transcription 3), with binding energies ranging from −3.98 to −3.88 kcal/mol, and exhibited similar binding modes and energies to nifuroxazide. Interestingly, the trifluoromethyl substituted 18 interacts in the coiled‐coil, DNA‐binding and linker domain of STAT3, with a binding energy of −4.16 kcal/mol.

Synthesis of pyrimidofuroxan-nucleoside derivatives and preliminary study of their activities

Synthesis of Janus Type Nucleoside Analogues and Their Preliminary Bioactivity

Synthesis, Crystal Structures, Fluorescence and Xanthine Oxidase Inhibitory Activity of Pyrazole-Based 1,3,4-Oxadiazole Derivatives

Synthesis and biological activity of novel 1,3,4-oxadiazole derivatives containing a pyrazole moiety

Synthesis of Novel Furozan-Based Nitric Oxide-Releasing Derivatives of 1-Oxo-oridonin with Anti-Proliferative Activity

Synthesis and Anti-tumor Activities of Novel Pyrazole Derivatives Containing 1,3,4-Oxadiazoline

Synthesis and Biological Activity of New 7-Amino-oxazolo[5,4-d]Pyrimidine Derivatives

Synthesis and biological evaluation of novel hybrids of phenylsulfonyl furoxan and phenstatin derivatives as potent anti-tumor agents

Discovery of novel furo[2,3-d]pyrimidin-2-one-1,3,4-oxadiazole hybrid derivatives as dual antiviral and anticancer agents that induce apoptosis

Synthesis and Antitumor Evaluation of Novel Hybrids of Phenylsulfonylfuroxan and Estradiol Derivatives

Synthesis and evaluation of biological and antitumor activities of 5,7-dimethyl- oxazolo[5,4-d]pyrimidine-4,6(5H,7H)-dione derivatives as novel inhibitors of FGFR1.

Studies on the Syntheses of 3-(β-D-Xylopyranosyl)-pyridazine and 3-(β-D-Xylopyranosyl)-4,5-dihydro-1H-6-pyridazinone

Synthesis of novel pyrazole derivatives as promising DNA-binding agents and evaluation of antitumor and antitopoisomerase I/II activities.

Synthesis and Biological Activity of 1,3,4-Oxadiazole-substituted Pyridazinones

Design, synthesis and biological evaluation of novel pyrimidine-phenylsulfonylfuroxan hybrids

Synthesis of New Nifuroxazide Derivatives Based on Nitropyrrole Skeleton with Good Antitumor Activity in Vitro

Synthesis and Antitumor Activities of Novel N6-Piperazine Substituted Adenosine Analogues

Design, synthesis and biological evaluation of novel hybrids of quinazoline derivatives and phenylsulfonylfuroxan as potential anti-tumor agents

Synthesis and Antiphytopathogenic Activity of Novel Oxazolidine-2,4-diones Bearing Phenoxypyridine Moiety.

Synthesis Of 1-[2-(Hydroxymethyl)-1,3-Oxathiolanyl]Pyridinone Analogues

Synthesis of Novel Nucleoside Analogue Phosphorothioamidate Prodrugs and in Vitro Anticancer Evaluation Against RKO Human Colon Carcinoma Cells